Micell Technologies Overview

  • Year Founded
  • 1995

Year Founded

  • Status
  • Out of Business

  • Employees
  • 14

Employees

  • Latest Deal Type
  • Out of Business

Micell Technologies General Information

Description

Developer of drug delivery systems designed to treat cardiovascular diseases and transform patient outcomes. The company's systems use supercritical fluid technology that limits the duration of polymer exposure, optimize healing, more precisely and consistently control drug elution, enabling physicians to improve safety and clinical outcomes.

Contact Information

Website
www.micell.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • P.O. Box 110025
  • Durham, NC 27709
  • United States
Primary Industry
Drug Delivery
Other Industries
Therapeutic Devices
Pharmaceuticals
Vertical(s)
TMT, HealthTech
Corporate Office
  • P.O. Box 110025
  • Durham, NC 27709
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Micell Technologies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Out of Business 01-Apr-2021 Completed Out of Business
10. Later Stage VC (Series E) 14-Sep-2017 Completed Generating Revenue
9. Later Stage VC (Series D2) Completed
8. Later Stage VC (Series D1) 30-Sep-2011 Completed Generating Revenue
7. Later Stage VC (Series C) 15-Apr-2011 Completed Generating Revenue
6. Later Stage VC (Series B2) 22-Sep-2009 Completed Generating Revenue
5. Later Stage VC (Series B1) 29-Jul-2009 Completed Generating Revenue
4. Later Stage VC (Series A) 05-Jul-2007 Completed Generating Revenue
3. Later Stage VC 21-Feb-2005 $2M $3M Completed Generating Revenue
2. Grant 01-Jan-2004 $295K $1M Completed Generating Revenue
To view Micell Technologies’s complete valuation and funding history, request access »

Micell Technologies Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series E
Series D2
Series D1
Series C
Series B2
Series B1 2,921,349 $0.004000 $0.33 $4.12 $4.12 1x $4.12 8.35%
Series A 1,712,375 $0.004000 $4.12 $4.12 1x $4.12 4.89%
To view Micell Technologies’s complete cap table history, request access »

Micell Technologies Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of drug delivery systems designed to treat cardiovascular diseases and transform patient outcomes. The company
Drug Delivery
Durham, NC
14 As of 2020

Uppsala, Sweden
 

Bedford, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Micell Technologies Competitors (4)

One of Micell Technologies’s 4 competitors is Beactica Therapeutics, a Venture Capital-Backed company based in Uppsala, Sweden.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Beactica Therapeutics Venture Capital-Backed Uppsala, Sweden
Ocular Therapeutix Formerly VC-backed Bedford, MA
Cantex Pharmaceuticals Formerly VC-backed Weston, FL
Humanetics Pharmaceuticals Venture Capital-Backed Roseville, MN
To view Micell Technologies’s complete competitors history, request access »

Micell Technologies Patents

  • 384

    Total Documents Applications and Grants

  • Total Patents Families

  • 137

    Granted

  • 6

    Pending

  • Expiring in next 12 mo

Micell Technologies Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2021122748-A Stents having biodegradable layers Pending 07-Feb-2020
EP-3862032-A1 Stents having biodegradable layers Inactive 07-Feb-2020
US-20210052781-A1 Transfer ring Inactive 17-Jan-2018
EP-3740323-A1 Transfer ring Inactive 17-Jan-2018
US-20180085498-A1 Prolonged drug-eluting products Inactive 23-Sep-2016 A61L31/16
To view Micell Technologies’s complete patent history, request access »

Micell Technologies Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ready to get started?

Request a free trial

Micell Technologies FAQs

  • When was Micell Technologies founded?

    Micell Technologies was founded in 1995.

  • Where is Micell Technologies headquartered?

    Micell Technologies is headquartered in Durham, NC.

  • What is the size of Micell Technologies?

    Micell Technologies has 14 total employees.

  • What industry is Micell Technologies in?

    Micell Technologies’s primary industry is Drug Delivery.

  • Is Micell Technologies a private or public company?

    Micell Technologies is a Private company.

  • What is Micell Technologies’s current revenue?

    The current revenue for Micell Technologies is .

  • How much funding has Micell Technologies raised over time?

    Micell Technologies has raised $145M.

  • Who are Micell Technologies’s competitors?

    Beactica Therapeutics, Ocular Therapeutix, Cantex Pharmaceuticals, and Humanetics Pharmaceuticals are competitors of Micell Technologies.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »